Catalyst Wire Dossier Catalyst Wire Dossier

Striverdi Respimat

olodaterol · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for Striverdi Respimat, covering 2011-11-22 to 2024-12-27. Get the full timeline:

Most recent: FDA Approved: STRIVERDI RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

See pricing